Correlation Engine 2.0
Clear Search sequence regions

  • cancer (1)
  • humans (1)
  • metastasis (8)
  • patients (4)
  • therapies (1)
  • Sizes of these terms reflect their relevance to your search.

    Metastasis-directed therapy (MDT)-local therapy that is intended to eradicate specific metastatic lesions-has hitherto been used with varying degrees of clinical efficacy and acceptance as a meaningful therapy for metastatic disease. Over the past 25 years, however, the momentum for using MDT to manage patients with metastatic solid tumours has increased, driven by several factors. Among these factors is the recognition that patients with limited metastatic burden could potentially derive survival benefits from MDT. Furthermore, although current systemic therapies are increasingly effective, they are infrequently curative. In addition, technological advances have broadened the spectrum of metastatic lesions that can be treated with ablative intent. Here we aim to briefly review the status of evidence for the clinical benefit of MDT based on current data mainly from trials in patients with oligometastatic disease, discuss the myriad of clinical states that might fall under and beyond the definition of oligometastasis, review technological advances in MDT and their applications beyond oligometastasis, and discuss the need for the continued co-evolution of MDT and systemic therapy as we seek to understand which patients with metastatic cancer can achieve durable remission and how to optimally manage those who cannot.


    Thomas H Beckham, T Jonathan Yang, Daniel Gomez, C Jillian Tsai. Metastasis-directed therapy for oligometastasis and beyond. British journal of cancer. 2021 Jan;124(1):136-141

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33204024

    View Full Text